Daiwa Securities Group Inc. Sells 1,782 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Daiwa Securities Group Inc. lowered its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 45.4% in the fourth quarter, HoldingsChannel reports. The firm owned 2,147 shares of the biotechnology company’s stock after selling 1,782 shares during the period. Daiwa Securities Group Inc.’s holdings in Sarepta Therapeutics were worth $261,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Janus Henderson Group PLC grew its holdings in Sarepta Therapeutics by 14.2% during the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after purchasing an additional 543,143 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after acquiring an additional 665,087 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after acquiring an additional 44,306 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Sarepta Therapeutics by 9.2% during the third quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock worth $94,148,000 after acquiring an additional 63,437 shares during the period. Finally, Erste Asset Management GmbH bought a new stake in shares of Sarepta Therapeutics during the third quarter worth approximately $79,425,000. Institutional investors own 86.68% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on SRPT shares. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Royal Bank of Canada reduced their price objective on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. HC Wainwright restated a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Scotiabank started coverage on Sarepta Therapeutics in a report on Friday, March 7th. They set a “sector perform” rating and a $105.00 price objective for the company. Finally, Needham & Company LLC restated a “buy” rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $170.41.

Sarepta Therapeutics Stock Down 1.2 %

Shares of SRPT opened at $97.19 on Monday. Sarepta Therapeutics, Inc. has a one year low of $97.06 and a one year high of $173.25. The company has a market cap of $9.43 billion, a P/E ratio of 77.75 and a beta of 0.79. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm has a 50 day simple moving average of $111.73 and a two-hundred day simple moving average of $119.82.

Insider Transactions at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.